Gas chromatographic assay for the new antitumor agent pyrazine-2-diazohydroxide (cas 103829-56-7) (diazohydroxide) and its stability in buffer, blood and plasma

Add time:07/17/2019    Source:sciencedirect.com

Diazohydroxide is a new antitumor agent being considered for clinical trial. A sensitive and specific assay for diazohydroxide in physiological media, plasma and blood has been developed based on conversion of diazohydroxide to 2-chloropyrazine in the presence of strong hydrochloric acid. The 2-chloropyrazine is extracted into the ethyl acetate and separated by capillary gas chromatography with nitrogen—phsophorus detection. Using 0.2 ml plasma the assay was linear up to 100 μg/ml diazohydroxide and had a lower limit of detectability for diazohydroxide of 50 ng/ml. The coefficient of variation of the assay at 1 μg/ml was 6.7%. Breakdown of diazohydroxide was rapid under mild acid conditions but slower under alkaline conditions. The half-life of diazohydroxide in 0.1 M sodium phosphate buffer, pH 6.0, at room temperature was 5 min and at pH 8.0, 480 min. Breakdown of diazohydroxide in plasma was biphasic. In fresh mouse plasma diazohydroxide had a terminal half-life at 37°C of 72 min while in fresh human plasma the terminal half-life was 23 min and in fresh blood 21 min. Diazohydroxide accumulated in red blood cells at 37°C to a concentration 68% above the concentration in plasma. Diazohydroxide was 49% bound to human plasma proteins at room temperature.

We also recommend Trading Suppliers and Manufacturers of pyrazine-2-diazohydroxide (cas 103829-56-7). Pls Click Website Link as below: cas 103829-56-7 suppliers

Prev:Stereoselective analysis of thioridazine-2-sulfoxide and thioridazine-5-sulfoxide: An investigation of rac-thioridazine biotransformation by some endophytic fungi
Next:Phase II Study of Pyrazine Diazohydroxide (NSC 361456) for Advanced Non–Small-Cell Lung Cancer)